What happened with CDXS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pharmaceutical manufacturers use Codexis’s enzymes to carry out chemical reactions in drug production. Codexis uses its proprietary CodeEvolver platform to design and optimize these enzymes, then sells them or develops them under customer agreements. Licensing and contracted research and development provide most revenue, with Merck licensing agreements an important source; enzyme sales provide the other main income stream.
Its established small-molecule business supplies enzymes for manufacturing approved drugs and clinical-stage candidates. A second business, ECO Synthesis, develops enzymes and processes for making RNA interference medicines. Customers pay for process development and small-scale production of material for preclinical testing at its Innovation Lab. These services already operate, but the platform’s commercial-scale manufacturing route is not yet commercialized. The lab produces material outside pharmaceutical good manufacturing practice standards, and Codexis plans to work with contract manufacturers to supply material meeting those standards for clinical trials and commercial use.
Revenue is heavily concentrated in a single customer. Enzyme orders depend on customers’ manufacturing schedules and clinical progress, and supply agreements generally do not require minimum purchases. Codexis also depends on outside manufacturers for commercial-scale enzyme production because its own capacity is limited.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Codexis’s growth also depends on contract drug manufacturers adopting enzymatic RNAi production, where privately held EnPlusOne Biosciences is an emerging competitor to watch.
Merck pays to use Codexis’s enzyme technology in making medicines it sells, so its licensing decisions can materially move Codexis’s revenue. Agreements signed in the second and fourth quarters of 2025 added $34 million to Codexis’s research and development revenue that year.
Agilent makes oligonucleotide drug ingredients for customers using established synthesis methods, giving drug developers an alternative to Codexis’s enzymatic RNAi platform. Its investment in RNA manufacturing capacity is worth watching as Codexis seeks adoption by contract drug manufacturers.
Pfizer’s future use of a licensed Codexis enzyme to manufacture medicines it sells could bring Codexis development and sales-based milestone payments. Watch whether Pfizer uses that enzyme in drug-substance manufacturing, which determines eligibility for those payments.
Novartis pays to use Codexis’s CodeEvolver platform to develop custom enzymes, tying Codexis’s licensing economics to the medicine seller’s use and commercialization of the technology. Progress toward commercial use matters more to this relationship than Novartis’s overall drug sales.
GSK’s progress with Codexis’s licensed CodeEvolver platform affects Codexis’s potential milestone and royalty receipts. GSK sells medicines and vaccines and uses the platform to develop custom enzymes; delays or a decision not to use the technology could reduce those receipts.
Ginkgo Bioworks competes with Codexis for customers’ biological development projects, selling research services and tools rather than making customers’ finished products. Its cell-engineering work is the business to watch for competition with Codexis’s paid enzyme-development services, rather than its mainly government-facing biosecurity business.
Merck & Co., Inc. earningsMRK
Merck’s report may show whether it is advancing use of Codexis’s licensed enzyme technology in medicines, a path that can bring licensing income to Codexis.
Look for evidence that Merck is advancing use of the licensed enzyme technology in medicine manufacturing, alongside Codexis’s research and development revenue, which includes licensing payments. Progress with supported Codexis revenue would suggest the collaboration is contributing; little evidence of progress and lower related revenue would make the 2025 Merck-related contribution harder to repeat.
Codexis, Inc. earningsThis company
Codexis’s report will show whether collaboration and licensing income is backing up enzyme sales or leaving the business exposed to uneven customer orders.
Read research and development revenue, which includes licensing and collaboration payments, alongside product revenue. Steady collaboration income with supported product sales would show both streams contributing. If collaboration income falls while product sales weaken, revenue is more exposed to payment timing from a small number of large customers and to shifts in enzyme orders.
Ginkgo Bioworks Holdings, Inc. earningsDNA
Ginkgo Bioworks’s report can show demand for its cell-engineering services, which compete with Codexis for paid enzyme-development projects.
Focus on Ginkgo Bioworks’s cell-engineering business, not its mainly government-facing biosecurity work. Stronger cell-engineering demand would suggest tougher competition for customer projects and make Codexis’s enzyme-development services harder to sell; weaker demand would ease that pressure, but would not prove customers are choosing Codexis instead.
Agilent Technologies Inc. earningsA
Agilent’s report can show how its oligonucleotide manufacturing business and capacity are developing, offering drugmakers an alternative to Codexis’s enzymatic RNAi route.
Watch Agilent’s oligonucleotide manufacturing business and capacity investment. Expansion would show that drugmakers’ established manufacturing alternative is strengthening, making adoption of Codexis’s enzymatic RNAi platform harder to win; slower expansion would weaken that competitive signal, but would not mean customers have switched to Codexis.
